Transscleral drug delivery for posterior segment disease.
about
Ocular drug delivery.Drug delivery to the posterior segment of the eye for pharmacologic therapy.Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.Effect of topical nipradilol on retinal microvascular leukocyte adhesion in diabetic rats.Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema.Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat.Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule ruptureIntrascleral drug delivery to the eye using hollow microneedles.Subtenon Vs Intravitreal Triamcinolone injection in Diabetic Macular Edema, A prospective study in Chinese populationIntravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.Influence of permeant lipophilicity on permeation across human scleraOcular pharmacokinetics of naringenin eye drops following topical administration to rabbitsDrug delivery to the retina: challenges and opportunities.Transsclera Drug Delivery by Pulsed High-Intensity Focused Ultrasound (HIFU): An Ex Vivo Study.Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.Effect of eye pigmentation on transscleral drug delivery.Delivery of neurotrophic factors and therapeutic proteins for retinal diseases.Periocular routes for retinal drug delivery.Drug delivery from ocular implants.PPARgamma Agonists: Potential as Therapeutics for Neovascular RetinopathiesNovel approaches to retinal drug delivery.Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.MRI in ocular drug delivery.Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy.The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonideCharacterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis.Delivery systems for in vivo use of nucleic Acid drugs.Liposomes in topical ophthalmic drug delivery: an update.Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.Hydrogels for central nervous system therapeutic strategies.Application of clotrimazole via a novel controlled release device provides potent retinal protection.Therapeutic Options for Retinoblastoma.Scleral permeability varies by mouse strain and is decreased by chronic experimental glaucoma.Minimally invasive microneedles for ocular drug delivery.Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration.Influence of freeze-drying and γ-irradiation in preclinical studies of flurbiprofen polymeric nanoparticles for ocular delivery using d-(+)-trehalose and polyethylene glycolCharacterization of silicone pressure-sensitive adhesive episcleral implant for drug delivery.
P2860
Q30475605-86BD20A9-F5A1-4905-B5DD-F83E05A40A1AQ30478379-37C3F7F1-B337-4DF1-9E56-18E5066EA607Q30487756-7A2F284D-A6A7-4763-AF50-C7A1C7FDDBC7Q33257640-D9B8B40B-153C-4B9B-8A93-51A903416D68Q33325652-575FC47E-B655-44DE-8C3E-A9FAC9EFD21AQ33523210-B563D7F5-2831-4F09-8BAD-38B95B98C60EQ33576379-A88FD9DB-9015-4DE7-92DF-A43C5814029BQ33978350-20E107FA-5735-47B7-93F3-60CFE66AA761Q34001902-E96B581E-805F-4642-9CF7-EAC07313C8B7Q34015028-7ADA519B-A018-4176-B783-F16032C52C3CQ34233208-5AC33245-BB13-4CE2-9F98-7AC4260A86FBQ34862764-B9A4F768-11E8-4B26-9327-3BA13E787D23Q35116140-602D46E6-5CDF-46D9-AFE1-A725380516C8Q35403847-3104A212-42F3-471F-A230-999D3A205A6DQ35706804-DD3E5186-F118-4CF5-BF57-6490C87329A3Q35884964-8C503B4C-9159-4D88-A693-FEA99ECD906BQ36299936-EB4CE0A9-3548-4AB1-8E13-609CC2E5764AQ36316631-A0B438C0-E6C5-4754-8114-B1B920CC9F66Q36409058-91A9D982-A8E8-42E9-8C74-8DF5841FD5DEQ36676571-1FD12E7A-6BF3-49EB-9978-347356A2B916Q36903801-3C611D9A-916A-4503-8858-06029697900CQ36939218-9E5C663A-13FB-4B9B-87D7-226A63A19F1FQ37054230-B836E601-23D5-4BAC-841D-14BBC41DD690Q37088862-A24311CB-AEA3-4F98-84D1-C0C1C885116AQ37133083-F5CB38E5-77FF-4B98-8D73-65250F935665Q37209391-C3299732-96EE-4C32-BD25-92F923CF7A29Q37774343-AB042B95-C183-4803-BD20-15D6EE1ED8B7Q37928915-140839B5-8968-4FE9-AC45-8FF9810546EFQ38239330-23A03A90-736D-43E4-A1D5-0B6675288C29Q38368715-3F102B43-33FB-4C34-8099-3E48B1BE5CEEQ38651258-B2707278-F390-4257-9E5B-1643639BD0FEQ38838374-293BA81F-D246-43B2-A705-1225AE449E34Q38842907-C98E9D91-30A7-4F78-82AA-143BEE40D687Q38896982-AD96503F-E668-4056-BF67-346EF1B9BE9DQ38916649-8CAF3530-7F52-4B94-AEAC-CC562D602D59Q38934604-76EA30CC-CF1D-4ACE-A152-D29DAF1CEFAAQ38987118-CC20F0F0-EFBD-43C9-BF96-18FE8F496117Q39848234-5671E40B-3D75-4791-82E1-8ABDD9210A34Q40968052-D87CB71D-8C25-45CD-AA1B-38C883F194CFQ40999904-D2D6FA90-FE46-4653-A21B-4F648E988A4B
P2860
Transscleral drug delivery for posterior segment disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Transscleral drug delivery for posterior segment disease.
@ast
Transscleral drug delivery for posterior segment disease.
@en
Transscleral drug delivery for posterior segment disease.
@nl
type
label
Transscleral drug delivery for posterior segment disease.
@ast
Transscleral drug delivery for posterior segment disease.
@en
Transscleral drug delivery for posterior segment disease.
@nl
prefLabel
Transscleral drug delivery for posterior segment disease.
@ast
Transscleral drug delivery for posterior segment disease.
@en
Transscleral drug delivery for posterior segment disease.
@nl
P1476
Transscleral drug delivery for posterior segment disease.
@en
P2093
Edelhauser HF
Geroski DH
P356
10.1016/S0169-409X(01)00193-4
P407
P577
2001-10-01T00:00:00Z